China Human Vaccine Industry Report, 2016-2020
  • June 2016
  • Hard Copy
  • USD $2,700
  • Pages:151
  • Single User License
    (PDF Unprintable)       
  • USD $2,500
  • Code: ZYM078
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,900
  • Hard Copy + Single User License
  • USD $2,900
      

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in domestic vaccine supply capacity and vaccine circulation safety, China’s human vaccine import volume has showed a year-by-year decline in recent years, with the imports for 2015 totaling 173.9 tons, down 17.5% year on year.

Affected by China’s less-developed economy, existing national vaccine prevention policies and people’s awareness of epidemic prevention, free EPI vaccines prevail in China. But the market share is falling, with the free EPI vaccine lot release volume in 2015 accounting for about 74.3% of the total. The Chinese free human vaccine market is still dominated by the subsidiaries of China National Biotec Group—including Beijing Tiantan Biological Products, Chengdu Institute of Biological Products Co., Ltd., Shanghai Institute of Biological Products Co., Ltd., Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., and Changchun Institute of Biological Products Co., Ltd.—and state-owned enterprises like Institute of Medical Biology under Chinese Academy of Medical Sciences. In 2015, the EPI vaccine lot release volume of Chinese state-owned enterprises made up 72.6% of the total.

However, as China gradually relaxes controls on the vaccine market, private companies have unexpectedly emerged in extra EPI vaccine market segment in recent years, with the proportion increasing constantly. In 2015, their lot release volume accounted for 70% in this market segment. Furthermore, these enterprises hold a dominant position in haemophilus influenza B (Hib), human rabies vaccine, varicella vaccine, influenza vaccine, and other market segments.

Being upbeat about China’s human vaccine demand market and exports, many vaccine producers are stepping up vaccine R&D or expanding capacity.

So far, there are four enterprises in China, namely Walvax Biotechnology, Beijing Minhai Biotechnology, SINOVAC BIOTECH, and Lanzhou Institute of Biological Products, whose 13-valent pneumococcal conjugate vaccine (PCV13) have entered clinical research stage; recombinant HPV vaccines, developed by Shanghai Zerun Biotechnology, a subsidiary of Walvax Biotechnology, and Xiamen Innovax Biotech, have entered phase III clinical research phase.

In 2015, CFDA approved the production and registration application of the world's first inactivated Sabin strain polio vaccine, which was developed by the Institute of Medical Biology of the Academy of Medical Sciences. The vaccine was brought to market on June 30, 2015. Over the same year, the inactivated enterovirus 71 (EV71) vaccines (for hand-foot-mouth disease prevention), also developed by the Institute of Medical Biology of the Academy of Medical Sciences was made available after the approval from CFDA; SINOVAC BIOTECH and Wuhan Institute of Biological Products are applying for drug production license of inactivated enterovirus 71 (EV71) vaccines; Hualan Bio and Beijing ZhifeiLvzhu Biopharmaceutical (a subsidiary of Chongqing Zhifei Biological Products) have submitted the application of clinic trial of inactivated enterovirus 71 (EV71) vaccines.

Human Vaccine Revenue of Major Vaccine Companies in China, 2014-2015
000000人用疫苗_副本.png 
Source: China Human Vaccine Industry Report, 2016-2020 by ResearchInChina

China Human Vaccine Industry Report, 2016-2020 highlights the following:
20120114.gifOperating environment, overall situation, sales channel, etc. of China human vaccine industry;
20120114.gifSupply & demand, competitive landscape, import & export, and development forecast of the Chinese human vaccine market;
20120114.gifSupply & demand, competitive landscape, and market prices of 10 vaccine product segments in China, including hepatitis B vaccine, influenza vaccine, rabies vaccine, and pneumococcal vaccine;
20120114.gifOperation, vaccine business, and development prospects of 16 Chinese human vaccine companies.

1. Overview of Vaccine Industry
1.1 Definition & Classification
1.2 Industry Chain

2. China Human Vaccine Industry & Market
2.1 Overview
2.2 Operating Environment
2.2.1 International Market
2.2.2 Policy Environment
2.2.3 Biopharmaceutical Market in China
2.3 Status Quo
2.4 Supply & Demand
2.5 Competition Pattern
2.6 Dynamics
2.7 Sales Channel

3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Supply & Demand
3.1.2 Competition Pattern
3.1.3 Market Price
3.2 Meningococcal Vaccines
3.2.1 Supply & Demand
3.2.2 Competition Pattern
3.2.3 Market Price
3.2.4 Market Forecast
3.3 Hepatitis A Vaccine
3.3.1 Supply & Demand
3.3.2 Competition Pattern
3.3.3 Market Price
3.3.4 Market Forecast
3.4 Influenza Vaccine
3.4.1 Supply & Demand
3.4.2 Competition Pattern
3.4.3 Market Price
3.5 Hib Vaccine
3.5.1 Supply & Demand
3.5.2 Competition Pattern
3.5.3 Market Price
3.5.4 Market Forecast
3.6 Rabies Vaccine
3.6.1 Supply & Demand
3.6.2 Competition Pattern
3.6.3 Market Price
3.6.4 Market Forecast
3.7 Varicella Vaccine
3.7.1 Supply & Demand
3.7.2 Competition Pattern
3.7.3 Market Price
3.8 Pneumococcal Vaccines
3.8.1 Supply & Demand
3.8.2 Competition Pattern
3.8.3 Market Price
3.9 DTP Vaccine
3.9.1 Supply & Demand
3.9.2 Competition Pattern
3.9.3 Market Dynamics & Forecast
3.10 PoliomyelitisVaccine
3.10.1 Supply & Demand
3.10.2 Competition Pattern

4. China’s Import and Export of Vaccines
4.1 Export
4.1.1 Export Volume and Value
4.1.2 Export Country and Region
4.2 Import
4.2.1 Import Volume and Value
4.2.2 Import Country and Region

5. Major Vaccine Manufacturers in China
5.1 China National Biotec Group
5.1.1 Beijing Tiantan Biological Products Co., Ltd
5.1.2 Chengdu Institute of Biological Products Co., Ltd.
5.1.3 Shanghai Institute of Biological Products Co., Ltd.
5.1.4 Wuhan Institute of Biological Products Co., Ltd.
5.1.5 Lanzhou Institute of Biological Products Co., Ltd.
5.1.6 Changchun Institute of Biological Products Co., Ltd.
5.2 Hualan Biological Engineering Inc.
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 Clients and Suppliers
5.2.6 R&D Cost and Investment
5.2.7 Vaccine Business
5.2.8 Development and Prospects
5.3 Chongqing Zhifei Biological Products Co., Ltd.
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 Clients
5.3.6 R&D Cost and Investment
5.3.7 Development and Prospects
5.4 Walvax Biotechnology Co, Ltd.
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 Clients and Suppliers
5.4.6 R&D Cost and Investment
5.4.7 Development and Prospects
5.5 Sinovac Biotech Ltd.
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 R&D Cost and Investment
5.5.5 Development and Prospects
5.6 Liaoning Cheng Da Co., Ltd.
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 Gross Margin
5.6.5 Clients
5.6.6 Liaoning Chengda Biotechnology Co., Ltd.
5.6.7 Development and Prospects
5.7 Changchun BCHT Biotechnology Co. Ltd.
5.7.1 Profile
5.7.2 Operation
5.8 Changchun Changsheng Life Sciences Limited
5.8.1 Profile
5.8.2 Operation
5.9 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
5.9.1 Profile
5.9.2 Operation
5.10 Shenzhen Kangtai Biological Products Co. Ltd.
5.10.1 Profile
5.10.2 Operation
5.11 Dalian Hissen Bio-Pharm Co., Ltd.
5.11.1 Profile
5.11.2 Operation
5.12 NCPC GeneTech Biotechnology Development Co., Ltd.
5.12.1 Profile
5.12.2 Operation
5.13 Dalian Aleph Biomedical Co., Ltd.
5.13.1 Profile
5.13.2 Operation
5.14 Beijing Minhai Biotechnology Co., Ltd.
5.14.1 Profile
5.14.2 Operation
5.15 Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
5.15.1 Profile
5.15.2 Operation
5.16 Jiangsu SimcereVaxtec Bio-pharmaceutical Co., Ltd.
Classification of Vaccines
Vaccine Industry Chain
EPI Human Vaccine Varieties in China, 2015
Global Human Vaccine Market Scale, 2008-2015
Sales Value of the Global Top 5 Human Vaccine Manufacturers, 2008-2015
Main Mergers & Acquisitions in the Vaccine Industry Worldwide, 2005- 2015
Policies in Vaccine Industry
Revenue and Total Profit of Bio-pharmaceutical Industry in China, 2007-2014
China’s Human Vaccine Market Scale, 2007-2015
Major Human Vaccine Varieties and Producers in China
Gross Margin of Major Human Vaccine Manufacturers in China, 2007-2015
The Release and Percentage (by Volume) of EPI and Extra EPI Vaccines in China, 2007-2015
China’s EPI Human Vaccine Market Shares by Release, 2008-2015 (by Enterprise Property)
China’s Extra EPI Human Vaccine Market Shares by Release, 2008-2015 (by Enterprise Property)
Vaccine Revenue of Major Vaccine Enterprises in China, 2011-2015
Some Events Related to Vaccine Business of Foreign Enterprises in China, 2011-2015
Vaccine Distribution Channel in China
Lot Release Volume of Hepatitis B Vaccine in China by Dosage Form, 2007-2015
Hepatitis B Vaccine (CHO Cell) Suppliers and Lot Release Volume in China, 2008-2015
Hepatitis B Vaccine (Yeast) Suppliers and Lot Release Volume in China, 2007-2015
Market Prices of Hepatitis B Vaccine in Some Regions of China, 2014
Meningitis Morbidity and Mortality in China, 2008-2014
Meningococcal Vaccines Lot Release Volume in China by Type, 2007-2015
Suppliers and Lot Release Volume of A-Group Meningococcal Vaccines, 2007-2015
Suppliers and Lot Release Volume of A-Group Meningococcal Vaccine, 2009-2015
Suppliers and Lot Release Volume of A+C meningococcal vaccines, 2007-2015
Suppliers and Lot Release Volume of ACYW135 Meningococcal Vaccines in China, 2008-2015
Market Prices of Meningococcal Vaccines in Some Regions of China, 2015
Hepatitis A Morbidity and Mortality in China, 2008-2013
Hepatitis A Vaccine Lot Release Volume in China, 2007-2015
Hepatitis A Vaccine Suppliers and Lot Release Volume in China, 2007-2015
Market Price of Hepatitis A Vaccine in China, 2015
Consumption Forecast of Hepatitis A Vaccine in China, 2015-2020
Influenza Morbidity and Mortality in China, 2008-2013
H1N1 Influenza Morbidity and Mortality in China, 2009-2012
China’s Influenza Vaccine Lot Release Volume (by Type), 2007-2015
Suppliers and Lot Release Volume of Influenza Split Vaccine in China, 2007-2015
Influenza Subunit Vaccine Suppliers and Lot Release Volume in China, 2007-2012
Market Price of Influence Vaccine in China, 2015
Hib Vaccine Lot Release Volume in China, 2007-2015
Hib Vaccin Suppliers and Lot Release Volume in China, 2007-2015
Market Prices of Hib Vaccine in Some Regions of China, 2015
Sales Volume of Hib Vaccine in China, 2015-2020 (mln dosages)
Rabies Morbidity and Mortality in China, 2007-2014
Human Rabies Vaccine Lot Release Volume in China, 2007-2015
Human Rabies Vaccine Lot Release Volume in China by Type, 2007-2015
Human Vero Cell Rabies Vaccine Suppliers and Lot Release Volume in China, 2007-2015
Human BHK Cell Rabies Vaccine Suppliers and Lot Release Volume in China, 2007-2015
Market Price of Human Rabies Vaccines in Some Provinces/Cities of China, 2015
Demand Forecast of Human Rabies Vaccine in China, 2015-2020(mln person-portions)
Varicella Vaccine Lot Release Volume in China, 2007-2015
Suppliers and Lot Release Volume of Varicella Vaccine in China, 2007-2015
Market Price of Varicella Vaccine in Some Regions of China, 2015
Pneumococcal Vaccines Lot Release Volume in China, 2007-2015
Suppliers of 7-valent and 23-valent Pneumococcal Vaccines and Their Lot Release Quantities in China, 2007-2015
Market Prices of Pneumococcal Vaccines in Some Regions of China, 2015
DTP Vaccine Lot Release Volume in China, 2007-2015
DTPa Vaccine Suppliers and Lot Release Volume in China, 2007-2015
Poliomyelitis Vaccine Lot Release Volume in China, 2007-2015
Poliomyelitis Vaccine Suppliers and Lot Release Volume in China, 2007-2015
Export Volume and Value of Human Vaccine in China, 2009- 2015
Export Average Unit Price of Human Vaccine in China, 2009- 2015
China’s Human Vaccine Export Volume and Value by Country, 2015
Import Volume and Value of Human Vaccine in China, 2009-2015
Import Average Unit Price of Human Vaccine in China, 2009- 2015
China’s Human Vaccine Import Volume and Value by Country, 2015
Major Shareholding Companies of Tiantan Biological and Their Revenue, Net Income, 2015
Revenue and Operating Income of Beijing Tiantan Biological Products, 2009-2016
Revenue Breakdown of Beijing Tiantan Biological Products by Sector, 2008-2015
Revenue Breakdown of Beijing Tiantan Biological Products by Region, 2007-2015
Beijing Tiantan Biological Products’ Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2015
Beijing Tiantan Biological Products’ Revenue from Top5 Customers and % of Total Revenue, 2008-2015
Gross Margin of Beijing Tiantan Biological Products by Sector, 2008-2015
R&D Costs and % of Total Revenue of Beijing Tiantan Biological Products, 2009-2015
Main R&D Products and Progress of Beijing Tiantan Biological Products as of the end of 2015
Vaccine Revenue of Beijing Tiantan Biological Products, 2008-2015
Vaccine Lot Release Volume Breakdown of Beijing Tiantan Biological Products by Product, 2009-2015
Revenue and Operating Income of Beijing Tiantan Biological Products, 2015-2020E
Vaccine Varieties of Chengdu Institute of Biological Products
Vaccine Lot Release Volume Breakdown of Chengdu Institute of Biological Products by Product, 2009-2015
Vaccine Varieties of Shanghai Institute of Biological Products
Vaccine Lot Release Volume Breakdown of Shanghai Institute of Biological Products by Product, 2009-2015
Vaccine Lot Release Volume Breakdown of Wuhan Institute of Biological Products by Product, 2009-2015
Vaccine Lot Release Volume Breakdown of Lanzhou Institute of Biological Products by Product, 2009-2015
Vaccine Lot Release Volume Breakdown of Changchun Institute of Biological Products by Product, 2009-2015
Revenue and Operating Income of Hualan Biological Engineering, 2007-2016
Revenue Breakdown of Hualan Biological Engineering by Sector, 2008-2015
Gross Margin of Hualan Biological Engineering by Product, 2007-2014
Hualan Biological Engineering’s Revenue from Top5 Customers and % of Total Revenue, 2008-2015
Hualan Biological Engineering’s Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2015
Name List, Procurement Amount of Top 5 Suppliers and % of Total Procurement, 2015
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2008-2015
Lot Release Volume Breakdown of Hualan Biological Engineering by Product, 2011-2015
Vaccine Revenue and Gross Margin of Hualan Biological Engineering, 2008-2015
Revenue and Operating Income of Hualan Biological Engineering, 2015-2020E
Revenue and Operating Income of Chongqing Zhifei Biological Products, 2008-2016
Revenue Breakdown of Chongqing Zhifei Biological Products by Product, 2011-2015
Lot Release Volume Breakdown of Chongqing Zhifei Biological Products by Product, 2011-2015
Revenue Breakdown of Chongqing Zhifei Biological Products by Region, 2009-2015
Gross Margin of Chongqing Zhifei Biological Products, 2009-2015
Gross Margins of Chongqing Zhifei Biological Products’ Home-grown Vaccines, 2008-2015
Gross Margins of Chongqing Zhifei Biological Products’ Agent Vaccines, 2008-2015
Chongqing Zhifei Biological Products’ Revenue from Top5 Customers and % of Total Revenue, 2008-2015
Procurement Amount and % of Total Procurement of Chongqing Zhifei Biological Products’ Top5 Suppliers, 2012-2015
R&D Costs and % of Total Revenue of Chongqing Zhifei Biological Products, 2008-2015
Progress of Some Products under Research of Chongqing Zhifei Biological Products by the end of 2015
Revenue and Operating Income of Chongqing Zhifei Biological Products, 2015-2020E
Industrial Layout of Walvax Biotechnology
Revenue and Operating Income of Walvax Biotechnology, 2009-2015
Vaccines on the Market and Capacities of Walvax Biotechnology
Revenue Breakdown of Walvax Biotechnology by Product, 2009-2015
Lot Release Volume Breakdown of Walvax Biotechnology by Product, 2009-2015
Revenue Breakdown of Walvax Biotechnology by Region, 2010-2015
Gross Margin of Walvax Biotechnology by Product, 2007-2015
Walvax Biotechnology’s Revenue from Top5 Customers and % of Total Revenue, 2008-2015
Walvax Biotechnology’s Procurement from Top5 Suppliers and % of Total Procurement, 2008-2015
Progress of Projects under Construction of Walvax Biotechnology by the end of 2015
R&D Costs and % of Total Revenue of Walvax Biotechnology, 2009-2015
Progress of the Products under Research of Walvax Biotechnology by the end of 2015
Revenue and Operating Income of Walvax Biotechnology, 2015-2020E
Revenue and Profit of Sinovac Biotech, 2007-2016
Revenue Breakdown of Sinovac Biotech by Product, 2008-2015 (Unit: USD mln)
Vaccine Lot Release Volume Breakdown of Sinovac Biotech by Product, 2009-2015
R&D Costs and % of Total Revenue of Sinovac Biotech, 2008-2015
Revenue and Operating of Sinovac Biotech, 2015-2020E
Revenue and Operating Income of Liaoning Chengda, 2008-2016
Revenue Breakdown of Liaoning Chengda by Sector, 2008-2015
Revenue Breakdown of Liaoning Chengda by Region, 2008-2015
Gross Margin of Liaoning Chengda by Sector, 2008-2015
Liaoning Chengda’s Revenue from Top5 Customers and % of Total Revenue, 2008-2015
Human Vaccine Lot Release Volume of Liaoning Chengda Biotechnology, 2009-2015
Revenue and Net Income of Liaoning Chengda Biotechnology, 2012-2015
Revenue Structure of Liaoning Chengda Biotechnology by Product, 2012-2015
Name List and Revenue Contribution of Liaoning Chengda Biotechnology’s Top5 Customers, 2013-2015
Name List and Procurement Share of Liaoning Chengda Biotechnology’s Top5 Suppliers, 2013-2015
Revenue and Operating Income of Liaoning Chengda, 2015-2020E
Revenue and Operating Income of Changchun BCHT, 2009-2015
Vaccine Lot Release Volume and Percentage of Changchun BCHT, 2009-2015
Vaccine Lot Release Volume Breakdown of Changchun Changsheng Biotechnology by Product, 2009-2015
Vaccine Lot Release Volume and Percentage of Zhejiang Tianyuan Bio-Pharmaceutical, 2008-2015
Revenue and Operating Income of Zhejiang Tianyuan Bio-Pharmaceutical, 2013-2014
Assets and Liabilities of Zhejiang Tianyuan Bio-Pharmaceutical, 2013-2014
Vaccine Lot Release Volume and Percentage of Kangtai Biological, 2007-2015
Vaccine Lot Release Volume and Percentage of Hissen Bio-pharm, 2009-2015
Vaccine Lot Release Volume of NCPC GeneTech Biotechnology Development, 2009-2015
Lot Release Volume of Dalian Aleph Biomedical’s influenza split vaccine, 2009-2015
Revenue and Operating Income of Dalian Aleph Biomedical, 2013-2014
Assets and Liabilities of Dalian Aleph Biomedical, 2013-2014
Vaccine Lot Release Volume Breakdown of Beijing Minhai Biotechnology by Product, 2009-2015
Revenue and Operating Income of Beijing Minhai Biotechnology, 2013-2014
Assets and Liabilities of Beijing Minhai Biotechnology, 2013-2014
Vaccine Lot Release Volume Breakdown of Shenzhen Sanofi Pasteur Biological Products by Product, 2009-2015
Revenue and Operating Income of Shenzhen Sanofi Pasteur Biological Products, 2013-2014
Assets and Liabilities of Shenzhen Sanofi Pasteur Biological Products, 2013-2014

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号